FDA Peptide Vote: 6 of 7 Cleared, DSIP Rejected

The Short Version

Over two days in July 2026, an FDA advisory committee reviewed seven peptides and recommended six of them for legal pharmacy compounding — overruling the written advice of the FDA's own scientists in each of those six cases. The seventh, emideltide (better known as DSIP), failed by a single vote. Nothing is legal to compound today.

For the peptide community, this is the biggest regulatory moment in years — the strongest signal yet that compounds pushed to the margins in 2023 could be moving back toward a legitimate, pharmacy-based pathway. It is a genuine win, and worth celebrating as one.

It is also worth reading carefully, because the headlines are already blurring it. If you only skim, you would think peptides just got “approved.” They did not. Here is the sentence worth pinning to your fridge: this vote was not about whether these peptides work. It was about who is legally allowed to make them. Those are different questions, and untangling them is the whole story.

And here is the part almost no one has noticed. The one peptide the panel refused to clear was the one with the most human clinical evidence in the room. Emideltide came with double-blind, placebo-controlled trials behind it — more than BPC-157, KPV, TB-500 or MOTS-c can claim. Those trials are precisely why it lost: the FDA could actually scrutinize the data, and the data did not hold up. The peptides with no human trials at all had nothing to fail. Strikingly, the people who have actually used DSIP mostly agree with the panel on this one.

Three things in this article you will not find in the wire coverage: exactly why emideltide was voted down, straight from the FDA's own slide deck; the fact that the reviewed indications were far narrower than the popular uses in every day-two case — the FDA never evaluated epitalon for longevity or semax for cognition; and an honest answer to “when can I actually buy this from a pharmacy?” based on how long this exact process has taken before. Short answer on that last one: legally, nothing has changed for you yet, and the real clock is longer than almost anyone is telling you.

The Full Scorecard: All Seven Peptides, Both Days

Seven peptides went before the committee across July 23–24, 2026. Six received favorable recommendations to be added to the FDA's 503A compounding list; one, emideltide, was voted down 6–7–1. FDA staff had recommended against all seven. Every tally below was read into the record at the meeting.^[6][7]

Vote format: yes–no–abstain. Each peptide was voted on twice — once in its free-base form and once as the acetate salt — and every pair broke identically on both days. All seven outcomes are non-binding recommendations to the FDA about the 503A bulk drug substances list, not approvals. Note the last column: FDA's own reviewers recommended against all seven, and the committee sided with them exactly once. Note also the margins — across fourteen votes on a panel of 12 to 15 people, nothing was decided by more than three votes.^[7][8]

What the Committee Actually Voted On

The body that met is the FDA's Pharmacy Compounding Advisory Committee (PCAC). It does not approve drugs. Its job is narrow: to advise the FDA on which raw ingredients belong on something called the 503A Bulk Drug Substances List. A favorable vote is a recommendation about manufacturing permission, not a finding that a compound is safe or effective.

That list is the crux of everything, so it is worth 30 seconds of plain English. Under the Federal Food, Drug, and Cosmetic Act, licensed compounding pharmacies — specialty pharmacies that mix medications to order from an individual prescription — can only compound from bulk ingredients that the FDA has vetted and placed on the 503A list. If a substance is on the list, a pharmacy can legally buy it in bulk and make it into an injection for a patient with a prescription. If it is not on the list, doing so is off-limits.

Here is the scale of that list today, and it is worth sitting with. The codified 503A bulks list currently contains exactly six substances — Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, and thymol iodide. Five of the six are marked for topical use only. That is the entire list, as it stands in the Code of Federal Regulations, current as of July 23, 2026.^[20] Six peptides being added would more than double it.

Back in 2023, the Biden-era FDA looked at a batch of popular peptides and declined to add them, stating they “may present significant safety risks.” That decision is what pushed BPC-157, TB-500, and the rest into the legal gray zone they have occupied ever since — sold widely online under “research use only” labels, but off the sanctioned pharmacy pathway.^[19] This week's votes are the clearest move yet to reverse that. For the fuller regulatory backstory, see our breakdown of FDA peptide regulations in 2026 and the peptide compounding pharmacy ban.

One procedural wrinkle worth knowing, because it shaped the second day: the nominations for the Friday substances had actually been withdrawn, and the FDA told the committee it was reviewing them “at its discretion” anyway.^[13] Some members were visibly unhappy about being asked to vote on substances nobody was formally asking for. The same thing had happened with KPV on day one.

Day One, Briefly: Four Peptides, Four Yes Votes

On Thursday, July 23, the committee recommended all four peptides in front of it — BPC-157, KPV and TB-500 each at 8–6–1, and MOTS-c at 7–5–2. Reporters described an audible reaction when the first tally was read, because a compounding advisory panel had just voted against the FDA staff's written recommendation. Then it did it three more times.^[1][3][4]

The FDA reviewers' objection was more basic than “does it work.” It was “what, exactly, is it?” As the FDA's Russell Wesdyk told the panel, “We've never faced a problem of, ‘What is it?’… We can't create quality standards until we actually know what it is.”^[1] Here is where each of the four stood, and what the FDA found:

• BPC-157 — reviewed for ulcerative colitis. A 15-amino-acid synthetic peptide popular for gut, tendon and joint recovery. The only human trial reviewers could locate was a conference abstract of about 46 people, and in that study the peptide was given as an enema, not the injection people actually buy. Nearly all remaining evidence is animal and lab work. Reviewers also flagged three adverse-event reports tied to compounded injectables.^[2]
• KPV — reviewed for wound healing and inflammation. A three-amino-acid fragment of the hormone alpha-MSH. The FDA's reviewers found no human studies at all; every supporting study was preclinical. The parties who originally nominated KPV withdrew their nomination, and the FDA reviewed it anyway.^[5]
• TB-500 — reviewed for wound healing. A synthetic fragment of the protein thymosin beta-4, commonly stacked with BPC-157 in the recovery community. No human clinical studies supported the proposed use, and one lab study found the intact peptide did not close wounds in cultured cells. It is also on the World Anti-Doping Agency's prohibited list, and a compounding pathway would not change that — an athlete using it still forfeits eligibility.^[2]
• MOTS-c — reviewed for obesity and osteoporosis. A peptide derived from mitochondrial DNA, with no human studies behind the reviewed uses. The FDA found no record of any outsourcing facility ever compounding it. Its 7–5–2 tally was the softest of the day: two abstentions instead of one, and the bloc of newly appointed members that had voted unanimously yes on the first three cracked here, with one abstaining. It is also WADA-prohibited.^[3][5]

In the peptide community, the reaction was immediate and jubilant. This is roughly how it landed on X within the hour:

BIG NEWS: the FDA panel just voted “YES” for BPC-157.
KPV is next on the list.

Jul 23, 2026 · 88 likes · View on X →

💉 FDA Peptide Panel votes in favor of legalizing BPC-157!

8 Yes
6 No
1 Abstain

Jul 23, 2026 · View on X →

Notice the word “legalizing” in that second post. That framing is everywhere right now, and it is not right. One of the more grounded replies in those same threads put it plainly: “This is not final as FDA still has to approve it, this is only step 1.” That reply is more accurate than most of the coverage.

Here is the honest read on day one, and it is the same standard we apply to every compound on this site: a favorable vote is not new data. The evidence base for these four peptides is exactly as thin today as it was before the meeting. Nothing was discovered; a reconstituted committee weighed the same files differently than the agency's scientists did. That is not a knock on the peptides — thin evidence often means under-studied rather than disproven — but it is the honest starting line. For the study-by-study picture, see what 50+ clinical studies actually show and our are peptides safe primer.

Why Emideltide (DSIP) Was Voted Down

Someone in the community asked the right question within hours of the vote: is there anywhere that says why they voted against it? As far as we can tell, nobody answered publicly. So here is the answer, in detail, from the FDA's own 146-page briefing deck and the meeting record. The decisive problem was not that emideltide is dangerous. It was that the studies behind it used a completely different route of administration than the one nominated — and where the studies did match, they showed it not working.^[8]

The vote itself was 6–7–1 against — the only no of the entire two-day meeting, and the panel's first pushback on the FDA's behalf.^[9][12][14] One member switching sides would have produced a clean seven-for-seven sweep. Emideltide is a synthetic nonapeptide — a nine-amino-acid chain — and most people know it by the name DSIP, or delta sleep-inducing peptide.

The FDA reviewed it for three proposed uses at once: opioid withdrawal, chronic insomnia, and narcolepsy. Its conclusion was unambiguous: “A balancing of the criteria weighs against emideltide (free base) and emideltide acetate being placed on the 503A Bulks List.” The agency cited poor physico-chemical characterization, insufficient human safety data, immunogenicity risk, and “lack of evidence to support effectiveness for use in chronic insomnia, narcolepsy, and opioid withdrawal.”^[8]

The route mismatch: nominated subcutaneous, studied intravenous

Emideltide was nominated for subcutaneous injection — under the skin, the way peptide users actually dose. Every clinical study behind it used intravenous administration, straight into a vein. The FDA said so directly: “There is no study evaluating effectiveness to support use of emideltide via the nominated SC ROA for narcolepsy,” and it said the same for opioid withdrawal.^[8]

If you are new to this, here is why that matters more than it sounds. A drug delivered intravenously enters the bloodstream immediately and completely, producing a sharp, fully predictable peak. The same drug injected under the skin has to diffuse through tissue first, which changes how much of it reaches circulation, how fast, and for how long. Peptides are especially sensitive to this, because many are broken down by enzymes before they ever get where they are going. A compound that works IV can genuinely do nothing subcutaneously. It is not a paperwork technicality — it is a different drug exposure.

The evidence, graded

Now grade the underlying human record, indication by indication, as the FDA did:^[8]

• Narcolepsy: one single-patient case report, from 1984, describing a 35-year-old man. That is the entire human record.
• Opioid withdrawal: two small studies, both unblinded, uncontrolled and open-label — meaning everyone knew who was getting the drug and there was no comparison group.
• Chronic insomnia: the strongest file, and the one that sank it. One investigator's positive findings were contradicted by two double-blind, placebo-controlled studies (Bes 1992 and Monti 1987). The FDA's summary: the results “appear inconclusive and at best preliminary.”

Every one of those studies dates to the 1980s or 1990s. The FDA also reported that no outsourcing facility has ever told the agency it compounds emideltide. As the FDA's Katie Park put it to the committee, “there is a lack of safety and efficacy data to support using emideltide for treating insomnia, narcolepsy and opioid use disorder.”^[8]

The dissenting members said much the same in their own words. Kevin Zacharoff, MD, of Stony Brook: “as a clinician, as a member of another advisory committee, it's impossible for me to not take the FDA's recommendations at heart with respect to safety and efficacy.” Todd Durham, PhD, of the Foundation Fighting Blindness, voted no “primarily for low-quality evidence around efficacy, the poor characterization of the bulk drug substance and the fact that there are approved medical therapies for all proposed uses.”^[7] That last clause is worth holding onto: unlike most of the seven, emideltide was competing against approved drugs that already exist for all three conditions.

In public comment, John Hertig, board chair of the Collaborative for Evidence-Based Medicines, made the same case in three sentences: “there is a significant lack of evidence… the last study on this was 30 years old. It should not be shifted to routine care. I say no.”^[7]

The yes side had a coherent answer, and it is worth hearing. Bobby Harshbarger, the Tennessee state senator and pharmacist on the panel, explained his vote this way: “I voted yes because our duty is to apply the 503A standards, not the investigational new drug application standard. Of course, this vote doesn't approve a drug or indication. It permits patient-specific compounding under a valid prescription, not mass production for unidentified consumers or routine copying of commercially available drugs.”^[7] That is the cleanest articulation of the yes case anyone gave in two days, and it is a real argument: the 503A bar was never meant to be a clinical-trial bar.

The people who actually use DSIP mostly agreed with the panel

Here is the detail that makes this vote genuinely unusual, and the reason we are not writing this section as a loss. When the rejection landed, the reaction from experienced peptide users was not outrage. It was a shrug — and, from several of them, agreement.

DSIP is the only peptide I've found to have no effect 🤷

Jul 24, 2026 · Reply in thread · View the thread on X →

He was not alone. Another reply in the same thread read, “DSIP is such sh*t. I'm not surprised,” and a third was considerably less printable while making the identical point. This is a small, self-selected sample of people on X, not data — we want to be clear about that, and a handful of replies proves nothing on its own.

But notice what happened: the double-blind trials and the lived experience landed in the same place. That almost never happens in this space, in either direction. Usually the anecdote runs hot and the trials run cold, and you are left deciding which to trust. Here, two placebo-controlled studies from the 1990s found emideltide did not outperform placebo for sleep, and thirty years later the people injecting it independently report that it does nothing for them. When rigorous evidence and community consensus converge, that convergence is worth more than either one alone.

So the honest framing of this vote is not “DSIP lost.” It is: on the one peptide of the seven where we actually have controlled human data, the data said it does not work, the users say it does not work, and the panel agreed. The system worked exactly once this week — and it worked on the one substance where there was enough evidence for it to work on. Hold that thought, because it leads somewhere uncomfortable.

The Inversion: Why the Best-Evidenced Peptide Lost

Emideltide had more human clinical evidence than any other peptide of the seven — including double-blind, placebo-controlled trials, the gold standard. It is also the only one the panel rejected. The peptides that sailed through did so on essentially no human data at all. There was nothing there to critique.^[8]

Lay the files side by side and the pattern is hard to unsee:

• KPV, TB-500 and MOTS-c: zero human trials for the reviewed uses. All three recommended.^[2]
• BPC-157: one roughly 46-person conference abstract, using a route (enema) nobody uses. Recommended.^[2]
• Emideltide: multiple human studies including two randomized, double-blind, placebo-controlled trials — which found it did not work. Rejected.^[8]

The peptides with no trials had nothing to fail. Emideltide had trials, and it failed them. That is the inversion, and it cuts in a direction that should make everyone uncomfortable, on both sides of the argument.

If you are pro-access, the uncomfortable implication is that an absence of evidence functioned as an asset in that room. A committee weighing “is there a reason to say no?” finds fewer reasons when there is less to read. The compounds we know the least about got the easiest ride.

If you are a skeptic, there is an uncomfortable implication for you too. The committee's job under 503A is not to decide whether a substance is proven effective — it is to weigh characterization, safety, historical use and evidence of effectiveness together, for compounding under an individual prescription. Emideltide arguably lost on the criterion the panel was least asked to police, while three peptides passed with an evidentiary record that could not be evaluated at all. That is not obviously the right sorting either.

Read plainly, the vote does not tell you that epitalon and semax are better bets than DSIP. It tells you that the panel penalized disconfirmed evidence more harshly than absent evidence. For your own decisions, those two states are not the same thing, and it is worth being precise about which one you are dealing with. “Studied, and it did not work” and “never properly studied” call for different levels of confidence, and neither one is the same as “proven.”

The practical takeaway is not cynicism. It is a question you can ask about any peptide, including the six that passed: is the evidence here thin because the compound failed when it was tested, or thin because nobody has tested it? For emideltide the answer is now clear. For KPV, TB-500 and MOTS-c it is still genuinely open — and open is a better place to be than closed.

Narrower Than You Think: What the FDA Actually Reviewed

This is the single most useful thing in this article if you use epitalon or semax. In every day-two case, the indication the FDA reviewed was dramatically narrower than the reason people actually buy the peptide. The agency never evaluated epitalon for longevity. It never evaluated semax for cognition or focus. If you are celebrating because you think the FDA looked at the claims that got you interested, it did not.^[8]

The FDA evaluated only the middle column, and found the evidence insufficient for every entry in it. The right-hand column was never before the committee at all.^[8]

Epitalon was reviewed for insomnia. Only insomnia.

Epitalon is marketed almost entirely as a longevity and telomere compound. The FDA reviewed it as a sleep aid, and recommended against it there. Its conclusion: “A balancing of the criteria weighs against epitalon (free base) or epitalon acetate being placed on the 503A Bulks List,” citing poor characterization, a lack of historical compounding information, a lack of human safety data, and immunogenicity risk.^[8]

On effectiveness the agency was blunt: “There is a lack of evidence to support the effectiveness of epitalon for the proposed use of insomnia, a disorder which increases the risk for serious conditions… we did not identify studies evaluating the use of these substances in patients with insomnia, particularly when administered via the proposed SC ROA.” The literature it could find dealt with melatonin-metabolite effects, not with treating insomnia in patients. The panel recommended it anyway, 7–4–1.^[7][16]

Semax was reviewed for stroke and pain. Not cognition.

Semax is bought overwhelmingly as a nootropic — focus, memory, mental energy. The FDA reviewed it for cerebral ischemia, migraine, and trigeminal neuralgia, and recommended against it on all three. It is the only one of the seven approved as a drug anywhere: Russia has approved it for ischemic stroke and optic-nerve conditions.^[8]

The agency's conclusion followed the same template: “A balancing of the criteria weighs against semax (free base) and semax acetate being placed on the 503A Bulks List.” It flagged poor physiochemical characterization, insufficient safety data, immunogenicity risk, and a specific practical problem with the nominated nasal spray — “there is lack of information regarding how an appropriate container and pump for an intranasal spray product would be selected and qualified.”^[8]

On cerebral ischemia, the supporting evidence was animal studies, Russian-language papers, and work in healthy adults rather than stroke patients. The FDA: “There is insufficient evidence of effectiveness to support use of semax (free base) or semax acetate for cerebral ischemia… Professional society guidelines on the treatment of cerebral ischemia do not discuss semax-related BDSs.”^[8]

The migraine and trigeminal neuralgia file is the striking part. It rested on a single 1996 study — uncontrolled, unblinded, 12 people with migraine and 25 with trigeminal neuralgia. And that study largely showed semax not working. Only 4 of the 12 migraine subjects, a third, had their headache stop; 8 of 12 reported that pain was “not eliminated but became less severe.” On the other condition the FDA wrote plainly: “Semax was not effective in resolving pain for the majority of subjects with trigeminal neuralgia in the study.”^[8] The one human study on the table was, in substantial part, a negative result.

Two more safety notes the FDA raised, both worth knowing if you use semax: there is no safety data for the proposed subcutaneous route and no published human pharmacokinetic studies, so nobody has characterized what the compound does in the body over time; and semax may have antithrombotic properties — blood-thinning effects — which is a real concern given that one proposed use is in stroke patients, some of whom are already on anticoagulants.^[8]

The most telling exchange of the semax session came when a panelist asked what the intended ischemic-stroke indication actually was — prevention, acute treatment, recovery? An FDA staffer conceded the agency could not tell from the materials it had been given.^[7] The committee then voted 8–5–1 in favor.^[10]

The mismatch is already spreading — here is what it looks like

We are not raising this as a hypothetical. Within 48 hours of the vote, the narrower reality had already been compressed out of the coverage almost everywhere, including in places that are usually careful.

• Reuters described epitalon and semax as “used to support aging and treat migraines, respectively.”^[11] That is a reasonable shorthand for how people use them, but it is not what the FDA reviewed — and when a wire service compresses it, every outlet downstream inherits the compression.
• A widely followed functional-medicine account posted that the panel had voted to “FREE 6 peptides,” listing “Epitalon: sleep & longevity” and “Semax: brain protection.” Two errors in one graphic: the indications are wrong, and “FREE” implies a legality that does not exist.
• An enthusiast post announced “EPITALON IS IN” with the correct tally — 7–4 — followed entirely by longevity and telomere history. Insomnia, the only thing actually reviewed, went unmentioned. The right number, the wrong meaning.
• A vendor is already selling a “brain health stack” built around semax, marketed for “BDNF, focus, and cerebral blood flow” — none of which the FDA evaluated — and bundling it with Selank, which was never in front of the committee at all. That last move is the pattern to watch for: a reviewed substance used to lend borrowed legitimacy to an unreviewed one sitting next to it in the cart.

None of this requires bad faith from anyone. Compression is what happens to a complicated fact as it travels. But it means the burden of precision falls on you, and the question to ask of any headline or product page from here on is simple: reviewed for what?

The telomerase question: an open one, not a scare

The most serious safety point raised against epitalon deserves careful handling, because it is easy to overstate in either direction. In primary cultures of human fetal lung fibroblasts, epitalon “(i) increased expression of telomerase, and (ii) extended telomere length.”^[8] Telomerase is the enzyme that rebuilds the protective caps on chromosomes; most cancers switch it on to keep dividing indefinitely. That is the mechanistic basis for dissenters' concern about carcinogenic potential.

Now the nuance that most coverage is dropping. The animal data points the other way. Mouse studies from the early 2000s reported decreased tumor incidence and extended lifespan.^[8] The FDA's objection is not that epitalon has been shown to cause cancer. It is that nobody has ever run the study that would tell you. Dr. David Baker of Elysium Health conceded exactly this on the record: “dedicated carcinogenicity studies have not been performed. So the risk is at present theoretical rather than demonstrated.”^[7]

That is the accurate framing, and it is the one to carry with you: uncharacterized, not disproven, and not demonstrated. An open question on a compound taken for years at a time is a real consideration. It is not a reason for panic, and anyone telling you epitalon is proven to cause cancer is going past the evidence just as much as anyone telling you it is proven safe.

The “approved in Russia” claim about epitalon is about a different substance

This one is a genuine correction, and it came out of a panelist's question. Asked whether epitalon is registered as a drug in Russia, the FDA's Ashlee Mattingly, of the Office of Compounding Quality and Compliance, answered on the record: “epitalon is not registered in any of the national medical registries that we searched. Epithalamin, which is a completely different substance, is what is approved and what was referenced by one of the open public speakers — that is registered in Russia.”^[7]

In plain terms: epithalamin is a peptide extract of pineal gland tissue, approved in the USSR in 1990. Epitalon is a synthetic four-amino-acid peptide developed to mimic it. They are related, but they are not the same product, and the regulatory approval belongs to the older one. If you have seen the “approved in Russia since 1990” line in vendor copy or a forum thread — and it circulates constantly — it is being applied to the wrong substance.

An industry speaker who refused to oversell

The most unexpected moment of day two came from the industry side. Testifying in the open public hearing, Elysium Health's Dr. David Baker said: “We agree with FDA that efficacy data regarding epitalon for longevity are largely mechanistic and preclinical, and that they are drawn from a narrow group of investigators without independent, controlled replication. We do not ask the committee to credit the longevity marketing that surrounds this peptide. Our narrow and honest claim is this: Demand for epitalon exists.”^[7]

An industry representative telling a regulator not to believe his own sector's marketing is rare enough to be worth pausing on. It is also, frankly, the standard we would like to see everywhere in this space.

Who Was in the Room — and Who Wasn't

If a science panel overrules the scientists six times in two days, the next question is obvious: who was on the panel? The answer turns out to be more interesting than “a stacked committee,” because the panel was not the same panel from vote to vote. Its membership changed between topics on day two, and that arithmetic explains the outcomes better than any argument made in the room.^[7]

Start with the composition. The PCAC is normally stocked with academics and researchers. This one was reshaped for the meeting: eight members were appointed under the current administration, and six of those run clinics that offer peptide therapies. One voting member is a sitting Tennessee state senator whose mother, a member of Congress, had personally written to the health secretary asking that compounders be allowed to make these very peptides. On day one's first three votes, all eight new appointees voted yes as a bloc.^[1][18]

Attendance was fluid throughout. There were roughly 15 voting participants, but the roster changed between votes — and you can see it in the published tallies themselves. Thursday's first three votes each total 15 participants; the MOTS-c tally totals 14. Friday's numbers move more.

The panel was reconstituted between topics

Here is the sequence, reconstructed from the roll calls read into the record:^[7]

• Emideltide: 14 voters. The 6–7–1 rejection.
• Epitalon: 12 voters. Two members who had just voted no on emideltide were no longer participating. Dr. Elizabeth Rebello's withdrawal was announced from the chair: “due to unforeseen circumstances Dr. Elizabeth Rebello notified us that she cannot participate in the epitalon topic… she has gone to attend to that matter.” Dr. Kevin Zacharoff was simply absent from the epitalon roll call. His absence was not announced, and we are inferring it from the roll call rather than from any statement on the record.
• Semax: back to 14. Rebello was still out, and the chair noted that “Dr. Zamboni will not be participating in this topic” — but three new members were introduced specifically for the semax discussion.

Rebello is worth a second look, because she was not a marginal figure. She is the MD Anderson anesthesiologist who had delivered some of the sharpest dissents of day one, warning that the panel was “responding to a market-induced demand rather than a decision based on solid science” and challenging the harm-reduction premise head-on: “I'm also concerned with the argument that patients are getting it anyway. That actually goes against the Hippocratic oath, which is do no harm.”^[1] One of the committee's most consistent skeptics was absent for its closest clearing vote.

Now do the arithmetic, because it reconciles exactly. Emideltide drew 7 no votes. Remove Rebello. Remove Zacharoff. Move David Pope from no to yes. That leaves 4 — which is precisely epitalon's no count.

Stated carefully: epitalon did not clear a wider margin than emideltide because it persuaded anyone new. It cleared partly because two of the panel's most consistent skeptics were not in the room. Its yes count rose by exactly one, from 6 to 7. Everything else in the margin came from no votes disappearing rather than from minds changing. That is a structural observation, not an accusation — withdrawals happen, and Rebello's was for a stated personal reason. But if you want to know why the numbers look the way they do, this is the answer, and it is not persuasion.

Only one member actually flipped

Across two days, exactly one voting member broke ranks and came back. David Pope, PharmD, chief pharmacy officer at XiFin Pharmacy Solutions, voted yes on BPC-157 on day one — “I voted yes because it's time to put this decision back in the hands of the physician and pharmacist” — then no on emideltide, then yes again on epitalon and yes on semax.^[7] The yes-count drop from 8 on day one to 6 on emideltide was Pope switching (minus one) plus the panel shrinking from 15 voters Thursday to 14 Friday (minus one). The rest of the panel held its position all week.

Timothy Fensky, RPh, DPh, the liaison from the National Association of Boards of Pharmacy, abstained from all three Friday votes because NABP takes no position — but he used the floor to make a request that may matter more than any vote: “NABP urges FDA to use the time before any final rule to build an infrastructure or framework with NABP and the state boards of pharmacy… such as adverse event reporting.”^[7] There is currently no systematic way to find out when a compounded peptide hurts someone. If access broadens, that gap is the one that will decide whether broader access is actually safer.

A procedural wobble on the meeting's final vote

During the semax roll call — the last vote of the two-day meeting — Dr. Asare Christian said, “I voted no for the reasons earlier.” The chair circled back: “Dr. Christian, could you confirm your vote, please?” Christian replied, “It's getting too confusing. Dr. Christian, I voted yes for the same reason.” The chair then said, audibly unsure, “Okay, it's still a legitimate vote, right? I think so.”^[7]

We are reporting that straight, with no theory attached. A member misstated his own vote on the final tally of a two-day meeting, corrected it, and the chair accepted it while openly uncertain about the procedure. Given that no vote across fourteen ballots was decided by more than three, and that the panel numbered 12 to 15 people, it is worth knowing how thin and how informal the margins really were.

What the dissenters said

The members voting no were the more traditional voices, and they were consistent across both days. Alongside Rebello, Dr. Brian Lee of USC Keck said the randomized data suggested BPC-157 “may be no better than placebo,” adding, “this endorsement can be potentially harmful, and I cannot in good conscience vote yes.” One member captured the characterization problem from the voter's chair: “I'm voting on something here, but I don't know what that something is. It's kind of like a black box to me.”^[1]

On day two, Friedhelm Sandbrink, MD, the VHA's national program director for pain management, made the case against semax in one line: “I don't think we can skip the rigorous scientific studies that are needed when we endorse any kind of product and make it available.”^[7]

Supporters make a fair point that the clinic-affiliated members are exactly the clinicians with hands-on experience prescribing peptides — the people who have watched patients respond. As one committee member and clinic founder put it on day one, “Once you see the effects of BPC, you can't unsee it.” Critics counter that people who sell peptides for a living have an obvious stake in a yes. Both things are true, and you do not have to pick a villain to hold the structure in view: a panel weighted toward practitioners who benefit commercially from broader access voted, narrowly, for broader access, against the staff's written advice.

“Medical Freedom” vs. “Market-Induced Demand”

Strip away the procedure and both days were a collision between two arguments that never quite meet. One says people are already using these compounds and a pharmacy is safer than a bodega. The other says a large market is a reason to study a product, not to legitimize it. If you use peptides, you have probably made the first argument yourself.

The case for yes is harm reduction, and it is genuinely strong. Peptides like BPC-157 are already bought at enormous scale — from overseas suppliers, gray-market vendors, and, as Hims & Hers' chief medical officer told the panel, even a bodega in Queens. “The question in front of you isn't whether people will use these,” a telehealth chief medical officer told the committee. “They already are. It's whether they use them with a doctor and a licensed pharmacy or completely alone.” One member described a patient who brought in a “research-grade” product that turned out to be laced with MDMA — “that's not protecting the American people,” she said, voting yes.^[1]

Ricardo Rosselló, the former governor of Puerto Rico, put the harm-reduction case to the committee on day two in its sharpest form: “The 2023 restrictions did not raise the standards. They abandoned them. They sent patients to markets where those standards don't exist.”^[15] And Haleem Mohammed, MD, of Gameday Men's Health, who voted yes on semax, described the outcome to Reuters this way: “We didn't approve a drug. Nobody put a finished product on a shelf. We took a decision that patients are already making, and we try to keep it inside a system that has rules and regulations.”^[11] He also criticized the agency's review itself: “We watched the FDA's own review board lean on surface-level searches while hundreds of pages of research submitted on time for these meetings went unaddressed.”^[7]

The industry read it as a rout. Two separate trade groups claimed the week — the American Academy of Peptide Medicine said the panel had “voted to restore medical freedom and medical liberty for all of us” after day one, and the American Academy of Peptide Sciences called day two “a victory for both patients and personalized medicine.”^[11] They are different organizations, and both were describing a recommendation, not a rule.

The case for no got its sharpest expression from Adriane Fugh-Berman, MD, of Georgetown, in day-two public comment: “Would the government endorse manufacturing heroin because it's cleaner than what is sold on the street? Just because a market is large doesn't mean that a product should be legalized. It means that a product should be studied.”^[7]

That analogy is deliberately provocative, and it deserves an honest answer rather than a dismissal. The strongest version of her point is not about heroin at all; it is that “people want it” is a fact about demand, and demand carries no information about whether something works or is safe. She is right about that — and the epitalon testimony proved it, since even the industry witness conceded that demand was his entire argument. Where the analogy strains is that heroin has a well-characterized harm profile and approved alternatives, while most of these peptides are unknown rather than known-dangerous. That is a different problem, and arguably one that a supervised pathway with real adverse-event reporting would help solve rather than worsen. Both halves of that are worth sitting with.

Critics across both days also warned that a 503A listing removes the incentive for anyone to ever run proper trials. A former FDA official put it bluntly on day one: any company that might prove a peptide works “will turn away from them, knowing that compounders will simply be able to sell them without ever needing to generate safety and effectiveness evidence.”^[3]

And then there is the point almost nobody reported, which may be the most important thing said in two days. Russell Wesdyk of the FDA's Office of Pharmaceutical Quality told the panel before the Friday votes: “It was shocking to me yesterday — and encouraging, frankly — how many speakers and even members of the committee here noted significant quality problems and asked for a yes vote, but with quality guardrails. But we lack the regulatory authority that put those guardrails in place.” He added: “Even before I can get to putting quality guardrails in place, we've got to establish an identity. So that's what I'd ask you to think about as we go through these votes today.”^[7]

Read that twice. Members were voting yes on the condition that safeguards be added — safeguards the FDA told them, on the record, it has no power to impose. That is not an argument for either side. It is a gap in the machinery, and it is exactly why Fensky's adverse-event-reporting request matters more than it sounds.

Here is the honest reconciliation, and it is the position we hold on this site: both arguments are true at once. People are going to use these compounds regardless, and a regulated pharmacy pathway really is safer than a bodega — and a regulatory nod can imply a scientific blessing the data has not yet earned. Six favorable votes are good news for access. They are not, by themselves, evidence that any of these peptides work. The meeting resolved the politics, not the science.

What Actually Changes for You Today

The honest answer to “what changed this week” is: legally, for you, nothing — yet. No peptide became compoundable, purchasable, or FDA-approved on July 23 or 24. Six of them moved one step along a multi-year path, and one stopped. Here is what that means in practice.

• The votes are recommendations, not rules. The PCAC advises; it does not decide. The FDA is not bound by the outcome. Historically it usually follows PCAC — but this time PCAC went against the FDA's own staff on all six favorable votes, which makes the agency's next move genuinely unpredictable.^[17]
• Nothing is compoundable yet. Before any of these six can legally be compounded, the FDA has to add them to the 503A list through notice-and-comment rulemaking — a formal process in which the agency publishes a proposed rule, collects public feedback, and then issues a final rule. That has not started.^[18]
• “On the list” is not “FDA-approved” — and that is written into the regulation itself. This is the single best thing to keep in your back pocket. The rule governing the 503A list, 21 CFR 216.23(d), states in black letter that there are “inadequate data to demonstrate the safety or efficacy” of anything compounded from substances on the list, and that “any person who represents that a compounded drug made with a bulk drug substance that appears on this list is FDA approved, or otherwise endorsed by FDA… will cause the drug to be misbranded.”^[20] In other words, the government has already written down that the exact marketing claim you are about to see everywhere is illegal.
• Emideltide's rejection changes nothing about DSIP's status either. A no vote is also just a recommendation. DSIP was not banned this week; it sits exactly where it did before, off the 503A list and outside the legal compounding pathway — the same place the other six still sit.^[9]
• The gray market you use today is unchanged. “Research use only” vendors are not compounding pharmacies and are not covered by these votes. A panel recommendation says nothing about any specific vendor's identity testing, purity, or dosing accuracy. This is exactly the moment to be more careful about sourcing, not less. Our guidance on whether peptides are legal applies unchanged.

Will this make peptides more expensive — and will the gray market get squeezed?

This is the question with the most real anxiety behind it, and it deserves a straight answer rather than a cheerful one. One of the most-upvoted community reactions to the vote laid the fear out in a single line: compounders mark prices up several times over, then enforcement tightens on overseas suppliers, and users end up paying more for the same thing with fewer options. That is a coherent worry, not paranoia, and we are not going to tell you it is baseless.

Here is what can honestly be said. Nobody knows how pricing shakes out, and anyone promising you cheaper peptides is guessing. A legal pharmacy product carries costs a research vial does not: a prescriber, pharmacy overhead, USP-grade material, identity and potency testing, sterility assurance, real labeling. It is reasonable to expect a compounded peptide dispensed against a prescription to cost more per milligram than the same peptide bought as a research chemical. You would be paying for verification you currently do not get, which is a genuine thing to buy — but it is not free.

On the enforcement half of the fear: the votes themselves do nothing to overseas suppliers. Adding a substance to the 503A list expands what pharmacies may make; it does not create new authority over unapproved sellers, which the FDA already has. Whether attention shifts once a legal pathway exists is a separate policy question this meeting did not decide. The nearest analogy is the compounded GLP-1 experience, where a legal window opened and then closed and enforcement did intensify around it — but that turned on a shortage designation ending, a different mechanism entirely, so read the parallel loosely.

What we would actually watch: whether any rulemaking is paired with the adverse-event-reporting framework the state pharmacy boards asked for, and whether 503B outsourcing facilities enter at scale. Volume from outsourcing facilities is the thing that would most plausibly pull prices down. None of it is decided, and we will update this page when it is.

What the market did — and what it tells you

The trading around the meeting is a useful illustration, because professional investors made and then unwound the exact mistake this article is warning about. Hims & Hers spiked more than 10% intraday on Thursday after the BPC-157 vote, paring back to close up about 3.4% at $32.74. On Friday it opened higher at $33.44 and ran to an intraday high of $34.57 — a fresh high on the news — then reversed hard and closed at $28.09, down $4.65, or 14.2%, on 28.4 million shares. Reported drivers were profit-taking as traders absorbed that these are non-binding recommendations rather than final rules, plus the emideltide rejection landing that morning.^[24][25]

Analysts were more measured throughout. Leerink Partners called the outcome a “positive catalyst,” estimating a $2.2 billion annual telehealth market with Hims capturing roughly 20% — while keeping a Market Perform rating and a $25 price target, citing execution risk. Reuters cites analyst estimates of a $2–3 billion legitimized peptide market.^[11][15]

The lesson is the same one we are giving you about headlines. The market's first reading was “peptides just got approved.” By Friday afternoon, with real money at stake, it had re-read the fine print and repriced. You can skip the round trip.

Shabbir Imber Safdar of the Partnership for Safe Medicines predicted the public version of this precisely: “The committee's recommendation will inevitably be interpreted by many as an endorsement of broader clinical use. It is not. Patients won't read the fine print. They will hear one thing: the FDA said 'yes.'”^[15] Ilisa Bernstein, a former deputy director of the FDA's drug compliance office, put the other half to the Washington Post: “Demand is not a substitute for data that demonstrates patient safety.”^[17]

How Long Until You Can Actually Buy These From a Pharmacy?

Nobody can give you a date, and the honest historical answer is: longer than you have been told. ABC News reports the FDA “must review the meeting records, public comments and votes, then publish proposed rules and open them for feedback, a process that can take up to a year.”^[18] That is a fair description of the steps. The track record of those steps is considerably slower — and it is all public, so you can check it yourself.

Three concrete precedents, all verifiable in primary sources:

Sources: 21 CFR 216.23 (current as of July 23, 2026), the September 2019 Federal Register proposed rule, the FDA's 503A bulk substances page, and the Alliance for Pharmacy Compounding's contemporaneous account of the June 2022 glutathione vote.

The glutathione parallel is the one to sit with. A substance cleared this exact committee, by almost exactly the margin BPC-157 just cleared it by, four years ago — and it is still not on the list. A favorable PCAC vote is a necessary step. On this list, it has never been a sufficient one on any predictable schedule.

We want to be careful about tone here, because this is not a reason for gloom and it is not us walking back the good news. The vote is still the most favorable regulatory signal peptides have had in years, and six of seven is a genuinely strong result. The direction of travel is real. What the record tells you about is speed, not direction. Momentum is real; the clock is long; and anyone telling you to expect pharmacy access this year is selling something.

Knowing the real timeline is what protects you in the meantime. The gap between now and any final rule is precisely the window in which “FDA-approved!” marketing will be at its most aggressive and least true. A reader who understands that this clock runs in years, not weeks, is a reader who does not get taken.

What to watch, in order of how much it would change things

1. Whether the FDA opens rulemaking, and how fast. This is the only step that changes anything in practice. Watch for a proposed rule in the Federal Register naming these peptides.^[18]
2. Whether the FDA moves any of these onto its interim Category 1 list and exercises enforcement discretion in the meantime. That would effectively change conditions on the ground long before a final rule. It is unresolved, and it is the single most under-discussed variable in this whole story.
3. The next PCAC meeting, confirmed for before the end of February 2027. In closing remarks a committee member put it simply: “we know we're going to be back here in February.”^[6][7]

What about the peptides that weren't reviewed?

A lot of the genuine disappointment this week is not about DSIP at all — it is from people whose compound was never on the agenda. Here is the honest state of play, because it varies:

• Scheduled for the February 2027 meeting: LL-37 (cathelicidin), GHK-Cu, Dihexa acetate, Melanotan II, and PEG-MGF. If you use GHK-Cu, your compound at least has a date.^[6]
• Not on any announced agenda: Selank, CJC-1295, ipamorelin, and most of the rest of the catalog. No meeting, no nomination under review, no timeline. That is not a rejection — nothing has been decided about them — but their status is unchanged and likely to stay that way for a while.

That distinction matters commercially, and it is worth guarding. A peptide sold in a bundle next to a reviewed one has not inherited anything from that review. Selank did not get any closer to a pharmacy shelf this week. It simply was not there.

The Bottom Line

Over two days, a reconstituted FDA committee recommended six of seven peptides toward legal compounding — BPC-157, KPV, TB-500, MOTS-c, epitalon and semax — overruling the agency's own scientists on every one, and rejected only emideltide, by a single vote. For anyone who uses these compounds, that is real, and it is the most favorable regulatory signal peptides have gotten in years. The direction of travel is unmistakably toward access.

But a favorable vote is momentum, not proof, and four details cut against the celebration in ways worth carrying with you. The one peptide with genuine controlled trials behind it is the one that lost, because those trials showed it did not work — and the people who have used it agree. The FDA never reviewed epitalon for longevity or semax for cognition; it reviewed them for insomnia and for stroke and pain, and found the evidence insufficient there too. Two of the panel's most consistent skeptics were absent for the epitalon vote. And a substance that cleared this same committee four years ago is still not on the list.

The FDA's own closing words, after two days of being overruled, were gracious and quietly pointed: “we also appreciate the constructive criticism across both days. It was always respectful and taken in the spirit in which it was given… We aren't always able to fix things for reasons that I don't even have to go into, but we will take everything that you said to heart.”^[7]

Our position on this site has not moved, and it is a pro-peptide one precisely because it is honest: know what a compound's evidence actually is, know exactly where yours comes from, and do not let a regulatory headline — or a vendor quoting one — stand in for a clinical trial or a trustworthy source. If you are new to all of this, start with what are peptides. Then read the individual pages for BPC-157, KPV, TB-500, MOTS-c, epitalon, semax, and DSIP before you decide what this week means for you personally.